All

New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH

71% of pegcetacoplan-treated patients achieved LDH normalization vs. 15% of eculizumab-treated patients 73% of pegcetacoplan-treated patients achieved a clinically meaningful improvement in FACIT-fatigue score vs. 0% of eculizumab-treated patients   Detailed results from positive head-to-head Phase 3 PEGASUS study in patients with paroxysmal nocturnal hemoglobinuria…

Epidarex Continues Expansion of Its Team

Epidarex Capital, a leading transatlantic early stage life science venture capital firm, is delighted to announce that Russell Makepeace has joined its management team as Vice President of Finance and Administration. Russell is an international business executive with over 25 years of experience in finance, accounting…

NodThera Announces Close of $55 Million Series B Financing

Financing round led by Novo Ventures and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as well as existing investors 5AM Ventures, F-Prime Capital, Sofinnova Partners and founding investor Epidarex Capital  Proceeds to support advancement of pipeline of small molecule NLRP3 inflammasome inhibitors, including…